

HUV`Y`cZ7 cbhYbly

GYW]cb

DU Y

Ù&] ^Á ăÁÚ` !][•^	H
Öã•[` ă] Á^• ăÖ^•ă } Áă ăÁÚăă } ă^	FF
Öã•[` ă] Á^• ăÚ] ^&ăăăă } Úăă ăăăăÁÚ!^] ăăăă }	FG
Öç!Áăăăăă }	FG
Ú!^á) ă [] ^ÁÚ` ăăăăăă } ÁÚă * ^ÁÚăă ^	FG
Ú!^á) ă [] ^ÁÚ` ăăăăăă } ÁV, [ÁÚăă ^	FÍ
FGG FÍ ĘFÍ GÜ€	FJ
ÖÙÙUÁÚ	Ĝ
Û^ [: ăă ăÖ^ ă^!^ ÁÚ] ă] •	Ĝ
Ú^ ^&c^ăÁÚă } ăă !^ÁÚ] ă] •	Ĝ
Ô`•đ { ^!ÁÖ] ! çăă	Ĝ
Š^* ăăÁ [ăă^	Ĝ

U] ǫ } ǫÁ^•dK

ǫǫ Á] ǫ } ǫÁǫǫǫǫ } ǫÁ•ǫǫǫǫ Á [ǫǫ &~ á^áǫǫ Á@Á ǫǫ áǫǫǫǫǫǫǫ

ǫǫǫǫǫ } ǫÁ^ǫ [ǫ dK

ǫǫǫǫǫ } ǫÁ ^ǫ~ !^ { ^ } ǫǫǫǫ ^ǫǫ !ǫǫ•ǫǫ ǫǫǫ ^ǫǫ!ǫǫ [, ǫǫ {] ^ǫǫ !^ǫǫǫ áǫ [Á] D

Ei U]Z]WU]cb`@Z'7 mWY'GHU] Yg

WÜÜK

W•^!ÁÜ^~ ǫ^ { ^ } ǫÁ ^ǫǫǫǫ } ǫǫǫǫ [& { ^ } ǫǫ ǫ } á^áǫǫ •d { ^ } ǫÁ•^

ÖÜK

Ö•ǫ } ÁÜ~ ǫǫǫǫǫ } ǫǫǫǫ [& { ^ } ǫÁ~ ǫǫǫǫǫ Á -ǫ •d { ^ } ǫǫ !ǫ ǫ } á^áǫǫ•^

ŬK

Ŭ•ǫǫǫǫ } ÁÜ~ ǫǫǫǫǫ } ǫǫǫǫ [& { ^ } ǫǫ @ǫ •ǫǫǫǫ } ǫ -ǫ @ǫ •d { ^ } c

UÜK

U] ^ǫǫ } ǫÁÜ~ ǫǫǫǫǫ } ǫǫǫǫ •ǫ Á@Á ǫǫ *^ǫ -ǫ•^

ÚÜK

Ú^!ǫ { ǫ } & ÁÜ~ ǫǫǫǫǫ } ǫǫǫǫ •ǫ Á@Á •ǫ { Á } á^!ǫ } áǫǫ } •ǫ -ǫ•^

ÜÜK

Ü^ǫ ǫǫ ÁÜ~ ǫǫǫǫǫ } ǫǫǫǫ •ǫ Á@ǫ •d { ^ } ǫǫǫǫ !ǫǫ ǫ •d { ^ } ǫÁ] ǫǫ

ÚT K

Ú]ǫ } ^áǫǫ ǫǫ ǫ } ǫ & Áǫ !ǫ & @ á~ !áǫǫ !^ǫǫ } ǫǫ^ǫ ǫǫ ǫ } ǫ &

FYZfYbW'Gci fWg

ǫǫǫǫ K

ǫǫ ^ǫǫǫ ÁÜ [&ǫ Áǫ !Á/^ǫǫ *ǫǫ áǫǫ ǫǫǫǫǫ

ǫǫǫ K

Wǫ ǫǫ áǫǫǫǫ•ǫǫ [áǫǫ áǫǫ~ *ǫǫ { ǫ ǫ dǫǫ }

ǫǫǫ Út K

ǫ [[áǫǫ ǫ { ǫǫ áǫǫ ǫ } ~ ǫǫǫ !ǫ * ÁÜǫǫǫǫ

ŬUK

Ŭ ǫ } ǫǫ } ǫÁÜ! * ǫ ǫǫ } Áǫ !ÁÜǫǫ áǫǫǫǫ ǫǫ }

WUJEEFK

WUÁÛcæ åæáÁ[;ÁÛ~ ææ Á' æ æ ^{ ^} óÁ•c{ •

ÚWUJK

Ú@æ{ æ^ ææÁ[] ^&ç } Á[[] ^!ææ } Á&@{ ^

WUÚK

Wj æ^ áÁÛcæ^ ÁÚ@æ{ æ[] ^æ

8 Jggc`i h]cb`HYgh8 Yg][b`UbX`F U]cbUY

GHUbXUF`DfYdUFU]cb

Ö^•&ā ǫ } hV@ Á•óš^•&ā^•Á@, Á Á!^} æ^Á ǫ āāā•Á! Á@ÁÚÁ•ó È

Ú! [&ā~ |^hÜ^~!Á Á!^!ā} ā [] ^Á! cāāā^Á! Á!^āā• È

: JHY`JU]XU]cb

Ö^•&ā ǫ } hV@ Á•óš^•&ā^•Á@Á!•Á•^āÁ! Á ǫ [|^Á} āÁ ǫ āāāÁ!^} āāā } È

Ú! [&ā~ |^hÜ^~!Á Á!^!ā} ā [] ^Á! cāāā^Á! Á!^āā• È
āā~ [ǫ~ •óš^Á^c^ ^} Á! Á ǫ āÁ€GĀ È

DfYXb]gcbY`Ei U]Z]WU]cb`!`G]b[`YGHU] Y

Ö^•&ā ǫ } hV@ Á@{ āāÁ•óš^!ā•Á@Á!^!{ ǫ &Á Á@Áš•[] ǫ } Á•ó!È

Ú! [&ā~ |^hÜ^~!Á Á!^!ā} ā [] ^Á! cāāā^Á! Á!^āā• È

DfYXb]gcbY`Ei U]Z]WU]cb`!`Hk c`GHU] Y

Ö^•&ā ǫ } hV@ Á@{ āāÁ•óš^!ā•Á@Á!^!{ ǫ &Á Á@Áš•[] ǫ } Á•ó!È

Ú! [&ā~ |^hÜ^~!Á Á!^!ā} ā [] ^Á! cāāā^Á! Á!^āā• È

C	Ùæè^ÁGÓ^ { ^dæÁT ^æ} Áſj , Áſä æK	NM	lí	Ã			
	Ùæè^ÁGÓ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íJ	Ã	ŠK	íJ	PK íJ
C	Ùæè^ÁGÓ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íi	Ã			
	Ùæè^ÁGÓ [^-æa) oſ Áææææ } Áſä æK	LM	îÈ	Ã	ŠK	îÈ	PK îÈ
C	Ùæè^ÁGÓ [^-æa) oſ Áææææ } Áſä æK	LM	íÈ	Ã			
	Ùæè^ÁGÓæ åæåÁÖä-!^) & Áſä æK	LM	GÈ	Ã	ŠK	GÈ	PK GÈ
	V^ {]^!æè !^ Áſj , Áſä æK	NM	Hí È	»Ô	ŠK	Hí È	PK Hí È
	V^ {]^!æè !^ Ápá @ſä æK	LM	Hí È	»Ô	ŠK	Hí È	PK Hí È
	Ùæè]jå * ÁÖ& :æè Áſä æK	LM	G	Ã	ŠK	G	PK G

† Áſj] ææè •KÁÖ { à!Á Áſ^•••!•Á•ç åKÁ ÁV^! ÁÖ-å åáÁMÚÁſä æ

	Òæè •^åÁVå ^ÁU^d [å çK	HE	{ å ç •		ŠK	HE	PK HE
	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Áſj , Áſä æK	NM	lí	Ã	ŠK	lí	PK lí
C	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Áſj , Áſä æK	NM	lí	Ã			
	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íi	Ã	ŠK	íi	PK íi
C	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íi	Ã			
	Ùæè^ÁFÖ [^-æa) oſ Áææææ } Áſä æK	LM	îÈ	Ã	ŠK	îÈ	PK îÈ
C	Ùæè^ÁFÖ [^-æa) oſ Áææææ } Áſä æK	LM	îÈ	Ã			
	Ùæè^ÁFÖæ åæåÁÖä-!^) & Áſä æK	LM	GÈ	Ã	ŠK	GÈ	PK GÈ
	Ùæè^ÁGÓ^ { ^dæÁT ^æ} Áſj , Áſä æK	NM	lí	Ã	ŠK	lí	PK lí
C	Ùæè^ÁGÓ^ { ^dæÁT ^æ} Áſj , Áſä æK	NM	lí	Ã			
	Ùæè^ÁGÓ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íJ	Ã	ŠK	íJ	PK íJ
C	Ùæè^ÁGÓ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íi	Ã			
	Ùæè^ÁGÓ [^-æa) oſ Áææææ } Áſä æK	LM	îÈ	Ã	ŠK	îÈ	PK îÈ
C	Ùæè^ÁGÓ [^-æa) oſ Áææææ } Áſä æK	LM	îÈ	Ã			
	Ùæè^ÁGÓæ åæåÁÖä-!^) & Áſä æK	LM	GÈ	Ã	ŠK	GÈ	PK GÈ
	V^ {]^!æè !^ Áſj , Áſä æK	NM	Hí È	»Ô	ŠK	Hí È	PK Hí È
	V^ {]^!æè !^ Ápá @ſä æK	LM	Hí È	»Ô	ŠK	Hí È	PK Hí È
	Ùæè]jå * ÁÖ& :æè Áſä æK	LM	G	Ã	ŠK	G	PK G

† Áſj] ææè •KÁÖ { à!Á Áſ^•••!•Á•ç åKÁ ÁV^! ÁÖ-å åáÁMÚÁſä æ

	Òæè •^åÁVå ^ÁU^d [å çK	HE	{ å ç •		ŠK	HE	PK HE
	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Áſj , Áſä æK	NM	lí	Ã	ŠK	lí	PK lí
C	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Áſj , Áſä æK	NM	lí	Ã			
	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íi	Ã	ŠK	íi	PK íi
C	Ùæè^ÁFÖ^ { ^dæÁT ^æ} Ápá @ſä æK	LM	íi	Ã			

	Úœ^ÁFÁ[^-āa) oĀ Áœāā } Šā āK	ŁM	I Ę	Ā	ŠK I Ę	PK I Ę
C	Úœ^ÁFÁ[^-āa) oĀ Áœāā } Šā āK	ŁM	I Ę	Ā		
	Úœ^ÁFÁÚœ āāāÁŌā-!^) & Šā āK	ŁM	GĚ	Ā	ŠK GĚ	PK GĚ
	Úœ^ÁGŌ[{ ^dāĀ ^ā } Šĭ , Šā āK	NM	I Ĩ	Ā	ŠK I Ĩ	PK I Ĩ
C	Úœ^ÁGŌ[{ ^dāĀ ^ā } Šĭ , Šā āK	NM	I Ĩ	Ā		
	Úœ^ÁGŌ[{ ^dāĀ ^ā } Áā @Šā āK	ŁM	Í J	Ā	ŠK Í J	PK Í J
C	Úœ^ÁGŌ[{ ^dāĀ ^ā } Áā @Šā āK	ŁM	Í J	Ā		
	Úœ^ÁGŌ[^-āa) oĀ Áœāā } Šā āK	ŁM	Í È	Ā	ŠK Í È	PK Í È
C	Úœ^ÁGŌ[^-āa) oĀ Áœāā } Šā āK	ŁM	Í È	Ā		
	Úœ^ÁGŌÚœ āāāÁŌā-!^) & Šā āK	ŁM	GĚ	Ā	ŠK GĚ	PK GĚ
	V^ {]^!æ ĩ^ Šĭ , Šā āK	NM	H Ę	»Ō	ŠK H Ę	PK H Ę
	V^ {]^!æ ĩ^ Áā @Šā āK	ŁM	H Ę	»Ō	ŠK H Ę	PK H Ę
	Úœ] ĭ * Áœ & ĩæ Šā āK	ŁM	G	Ā	ŠK G	PK G



USP REFERENCE STANDARD CERTIFICATE

DISSOLUTION PERFORMANCE VERIFICATION STANDARD - PREDNISONE

(10 mg nominal prednisone content per tablet)

USP Catalog No.:	1222818
USP Lot No.:	R182R0

Valid Use Date	31-JUL-2025
Storage/Handling	As per the label.
Uses	General Chapter <711> Dissolution, Performance Verification Test (PVT), Apparatus 1 and Apparatus 2

Dissolution <711>

- Medium: 499 g of degassed purified water maintained at 37° ± 0.5°
- Medium degassing: Recommended degassing procedure: Heat a suitable amount of water, while stirring gently to about 41-45°. Filter under vacuum through a 0.45-µm-porosity filter into a suitable filtering flask equipped with a stirring device. Seal the flask and continue to apply vacuum while stirring for an additional five minutes. Measured vacuum should be less than 100 mbar.
Note: Other validated degassing methods that reduce the total dissolved gas in the media can also be used
- Apparatus: Apparatus 1 (Basket) or Apparatus 2 (Paddle) at 50 RPM
Note: If equipment is dedicated for use with only one apparatus (basket or paddle), then performance verification is only required for that apparatus
- Time: 30 minutes
- Standard Solution: A known concentration of USP Prednisone RS in Medium.
Note: An amount of alcohol not to exceed 5% of the total volume of the standard solution may be used to bring the prednisone reference standard into solution.
- Sample solution: Laboratory can choose either Single-Stage Test or Optional Two-Stage Test scheme to obtain Sample Solutions.
A filtered portion of the solution under test, suitably diluted, if necessary, with Medium to obtain a concentration similar to that of the Standard solution.
Note 1: The filtering method must not cause adsorptive loss of drug
Note 2: Bias introduced by automated methods is to be avoided
- Analysis: UV at maximum absorbance of about 242 nm
- Procedure: Determine the quantity of prednisone, C₂₁H₂₆O₅, dissolved at 30 minutes in each vessel expressed as percent of the labeled amount.



USP REFERENCE STANDARD CERTIFICATE

Single-Stage Test Instructions and Acceptance Criteria

- For each position in the assembly, test one USP Dissolution Performance Verification Standard – Prednisone (DPVS – Prednisone) RS tablet, and record the percent dissolved at the sampling time point specified. Transform the percent dissolved results to the natural log scale, determine the mean and variance. For assemblies with 12 or 14 dissolution vessels, no further testing is required
- For assemblies with fewer than 12 positions, repeat Step 1 with an additional set of tablets. Transform the percent dissolved results to the natural log scale, determine the mean and variance.
- Calculate the average of the two means and of the two variances obtained in Steps 1 and 2. Use the results from Step 1 alone for assemblies that have 12 or 14 positions.
- Convert the results of Step 3 to a geometric mean (GM) and percent coefficient of variation (%CV). See Calculation Example for details.
- Compare the results of Step 4 to the Single-Stage acceptance criteria in Table 1. The GM must not fall outside the limits, and the %CV must not be greater than the limit. If both meet the criteria, the assembly has passed the PVT

Table 1. Performance Verification Test Acceptance Criteria for Single-Stage Test

Apparatus	No. of vessels per run	Geometric Mean, % Prednisone Dissolved	%CV
1 (Basket)	6	81-94	4.4
	7	81-94	4.3
	8	81-94	4.2
	12	81-94	4.3
	14	81-94	4.3
2 (Paddle)	6	45-57	5.4
	7	45-57	5.3
	8	45-56	5.2
	12	45-57	5.4
	14	45-57	5.3



USP REFERENCE STANDARD CERTIFICATE

Optional Two-Stage Test Instructions and Acceptance Criteria

A laboratory may choose to implement the PVT as a Two-Stage test in case of assemblies with less than 12 positions. The Two-Stage test is a statistically valid means of allowing the possibility of stopping the test at the first stage using more stringent acceptance criteria. The following are step-by-step instructions for the two-stage test

1. For each position in the assembly, test one USP DPVS – Prednisone RS tablet, and record the percent dissolved at the sampling time point specified. Transform the percent dissolved results to the natural log scale, determine the mean and variance
2. Convert the results of Step 1 to a GM and %CV and compare to the 1st Stage of Two Stages acceptance ranges in Table 2. The GM must not fall outside the limits, and the %CV must not be greater than the limit. For calculation of the GM and %CV, see Calculation Example for details
3. If results of Step 2 satisfy both acceptance criteria, the assembly has passed the PVT. Otherwise continue to Step 4. Prior to proceeding to Step 4, see Futility Factor section.
4. Repeat Step 1 with an additional set of tablets. Transform the percent dissolved results to the natural log scale determine the mean and variance for the data obtained at this step
5. Average the two means and two variances obtained in Steps 1 and 4
6. Convert the results of Step 5 to a geometric mean (GM) and percent coefficient of variation (%CV). For calculation of the GM and %CV, see Calculation Example for details
7. Compare the results of Step 6 to the 2nd Stage of Two Stages acceptance ranges in Table 2. The GM must not fall outside the limits, and the %CV must not be greater than the limit. If both meet the acceptance criteria, the assembly has passed the PVT

Table 2. Performance Verification Test Acceptance Criteria for Two-Stage Test

Apparatus	No. of vessels per run	First Stage of Two-Stage Test		Second Stage of Two-Stage Test	
		Geometric Mean, % Prednisone Dissolved	%CV	Geometric Mean, % Prednisone Dissolved	%CV
1 (Basket)	6	83-91	3.3	81-94	4.4
	7	83-91	3.3	81-94	4.3
	8	83-91	3.3	81-94	4.2
2 (Paddle)	6	47-54	4.1	45-57	5.4
	7	47-54	4.1	45-57	5.3
	8	47-54	4.1	45-56	5.2



USP REFERENCE STANDARD CERTIFICATE

Futility Factor

If optional Stage-Two test is chosen, there are circumstances when the %CV after the First Stage of Two-Stage test equals or exceeds the value in the Futility Factor table (without rounding). In such cases it is impossible to meet the %CV criterion after the Second Stage of the Two-Stage test. The lab can stop after the First Stage run. However, after any adjustments to equipment, test procedure, and so on, the PVT must be restarted with a new first run (Step 1 of the two-stage test instructions).

Futility Factor, %CV at or above value given, second stage testing will not produce passing result

Apparatus	Number of Vessels		
	6	7	8
1	6.2	6.1	5.9
2	7.6	7.5	7.4

Refer to this website for the USP Calculation Tool: <https://apps.usp.org/app/USPNF/pvtCalculationTool/>

Calculation Example (expressed as Microsoft Excel® worksheet functions):

Run 1: x_1, x_2, \dots, x_n in natural log scale: $\ln x_1, \ln x_2, \dots, \ln x_n$

Run 2: $x_{n+1}, x_{n+2}, \dots, x_{2n}$ in natural log scale: $\ln x_{n+1}, \ln x_{n+2}, \dots, \ln x_{2n}$

1st Stage of Two-Stage for n=6, 7, 8 and Single-Stage for n=12, 14:

$$GM1 = \exp(\text{average}(\ln x_1:\ln x_n))$$

$$\%CV1 = 100 * \sqrt{\exp(\text{var}(\ln x_1:\ln x_n)) - 1}$$

Single-Stage or 2nd Stage of Two-Stage for n= 6, 7, 8:

$$GM = \exp(\text{average}((\text{average}(\ln x_1:\ln x_n)), (\text{average}(\ln x_{n+1}:\ln x_{2n})))) = \exp(\text{average}(\ln x_1:\ln x_{2n}))$$

$$\%CV = 100 * \sqrt{\exp(\text{average}((\text{var}(\ln x_1:\ln x_n)), (\text{var}(\ln x_{n+1}:\ln x_{2n})))) - 1}$$

exp: exponential (e^x) var: variance sqrt: square root *: multiply 100: conversion factor to percentage


For more information and guidelines about how to complete the performance verification test refer to the following website: <https://www.usp.org/small-molecules/pvt>





USP REFERENCE STANDARD CERTIFICATE

Label



REFERENCE STANDARD

DISSOLUTION PERFORMANCE VERIFICATION STANDARD - PREDNISONE 30 Tablets

For use with specified USP compendial tests. Not for use as a drug. See SDS prior to use at www.usp.org/sds.

⚠ The nominal weight of prednisone in each tablet is 10 mg. At the time of use, open the aluminum sachet, remove the blister card, and push the tablets through the foil backing of the blister card. Use only whole tablets. Store at controlled room temperature. Keep unused or unopened blister strips in the secondary package.


Danger! Causes eye irritation. Suspected of damaging fertility or the unborn child. Causes damage to organs (endocrine system) through prolonged or repeated exposure.

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust/fume/gas/mist/vapors/spray. Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection. If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. If exposed or concerned: Get medical advice/attention. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.

See certificate for any additional information.

USP, 12601 Twinbrook Pkwy, Rockville, MD, +1-301-881-0666
Cat. No. 1222818 Material mfd. in Spain

LOT: R182R0



Danielle A. Vattimo

Quality Assurance

Certificate Version History

Version Number	Date	Reasons for Change
00 (Current)	14-MAR-2024	First issue



USP REFERENCE STANDARD CERTIFICATE

Label

Reference Standard label typically contains the name, catalog number, lot number, package size, assigned value when applicable, storage conditions, handling instructions, and country of origin information. The label may also include hazard and precautionary statements required by the Occupational Safety and Health Administration (OSHA).

Assigned Value

For USP Reference Standards with compendial quantitative use(s), an assigned value is provided on the label and/or the Certificate.

For USP Reference Standards with compendial qualitative use(s), USP may choose to provide a value, e.g., chromatographic purity, for informational purposes in the Certificate, on a case-by-case basis.

Valid Use Date

It is the responsibility of the user to ascertain that a particular lot of a USP Reference Standard has official status either as a "Current Lot" or as a "Previous Lot" within the assigned valid use date. The online USP Reference Standards Catalog and the online USP Store at www.usp.org are updated daily. USP recommends referring to one of these sources prior to using a USP Reference Standard to make sure the lot is valid for use.

Storage

Storage conditions are lot-specific and may change from one lot to another. Storage conditions on the label and/or the Certificate are valid for unopened container as received. Once the container is opened, unless otherwise specified on the label and/or the Certificate, users are responsible for storing any remaining material according to their site procedures and ensuring continued suitability for its intended use. If no specific directions or limitations are provided on the label, conditions of storage include storage at room temperature and protection from moisture, light, freezing, and excessive heat. See General Chapter <659> in the USP-NF Online for storage and handling definitions.

Instructions for Use

Follow the instructions provided on the label and/or the Certificate and in the associated USP documentary standard(s). Please refer to General Chapter <11> for additional information.

Non-USP Compendial Use

USP Reference Standards are for use in analytical or laboratory applications generally as specified in USP compendia. They are not for use in humans or animals as drugs, food, or medical devices. It may be possible to use a USP RS outside of its associated USP compendial applications; however, it is the responsibility of the user to determine the suitability of the USP RS for a non-USP use.

LEGAL NOTICE

USP WARRANTS GOOD TITLE TO USP REFERENCE STANDARDS ON DISPATCH FROM USP. THE FOREGOING WARRANTY IS IN LIEU OF ANY OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY THAT THE PRODUCTS, INCLUDING THIS CERTIFICATE, ARE OF MERCHANTABILITY QUALITY. USP'S LIABILITY ARISING OUT OF OR RELATING TO THE SUPPLY OF USP REFERENCE STANDARDS AND THIS CERTIFICATE SHALL IN NO EVENT INCLUDE LOSS OF PROFITS, COST OF PROCURING SUBSTITUTE GOODS OR SERVICES, OR ANY INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES OF ANY KIND, EVEN IF USP IS AWARE OF THE POSSIBILITY OF SUCH DAMAGES. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, USP DOES NOT WARRANT THAT THE USE OR RESALE OF USP REFERENCE STANDARDS, INCLUDING THEIR USE TO PERFORM TESTS AND ASSAYS PUBLISHED BY USP, WILL NOT INFRINGE UNITED STATES OR ANY OTHER PATENTS.

USP Reference Standards are not intended for use as drugs, food, or as medical devices.

This certificate may not be reproduced without the express written permission of USP.



Standard PQ Test Suite

This document describes the test program for qualifying dissolution instruments, and the following tables list all PQ tests. PQ affirms that your dissolution apparatus performs in accordance with current USP requirements. The USP Dissolution Performance Verification Test (PVT) is performed as required in the current USP General Chapters, Dissolution <711> and Drug Release <724>, in accordance with cGMPs.

Note: The actual test limits are subject to change when a new prednisone standard is released. A custom EQP is available with limits for the current USP lot.

Test	Setpoints and Parameters	Limits
Standard Preparation	N/A	% Absorbivity $\geq 99.0\%$ and $\leq 101.0\%$ for working and control standards (calculations are performed <u>only</u> if the control standard is used)
Filter Validation	N/A	Recovery $\geq 98\%$ and $\leq 102\%$ for each filtered aliquot
Prednisone Qualification (All variations of test)	Vessel temperature: 37.0°C Elapsed time: 30 minutes (target window from tablet drop to sampling)	See current USP lot's Certificate of Analysis

Consumables, Supplies, and Parts Used for Qualification

All parts, supplies, standards and consumables specified by the Agilent qualification protocol are provided by the customer. Agilent does not provide Prednisone standards due to the impact of improper storage, which can adversely affect the potency and/or purity of the standards and put the integrity of the qualification at risk. Agilent will provide equipment necessary for the measurement of physical parameters (e.g., thermometer, level, tachometer, wobble gauge, etc.). Any additional parts for maintenance or repair needed to affect qualification will be billed to customer unless otherwise covered by Agilent service and support agreement.

Test Design and Rationale

PQ service does not include physical testing (e.g., measurements of speed, wobble, centering, level, etc.). Because the physical condition of the Dissolution tester can affect the outcome of the Performance Qualification, it is recommended that an inspection of the equipment and measurements of physical parameters are performed prior to the service to ensure that the equipment conforms to pharmacopeia requirements.

Standard Preparation

Description: This test describes how to prepare standards for the PQ tests.

Procedure: Refer to prednisone certificate for details

Filter Validation

Description: This test validates the filters used for sample and standard preparation.

Procedure: This test compares absorbance readings of three filtered aliquots of working standard.

Prednisone Qualification

Description: These chemical tests verify the performance of the dissolution tester.

Procedure: Refer to prednisone certificate for details.

www.agilent.com/chem/qualification

Information, descriptions and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc. 2024
Published in USA

F YdcfhUbX'8 Y]j YfmCdh]cbg

V@ Áã oÁ^ [, Á & `á^ Á] ǫ } • Á ^ ^ & c^ Á : Á & ` • ǫ } Á @ Á Ò Ò Ò Ò Á ^ - æ | dÁ ^ ^ æ á Á ~ } Á [* • Á á Á á } • æ & ǫ } Á [* • Á á Á á , æ •
ǫ & ` á^ á Á á c @ : Á] ǫ } • Á á Á Á Á & ` á^ á Á : Á c & ` á^ á Á

ǫ [: Á @] @ } æ á Á ~ • c { Á } ^ Á } [D Á á - Á : ^ } ǫ [ǫ } • Á á Á @ • ^ } Á : Á @ Á : á æ á Á ~] [: á Á ~ • c { Á } ^ Á @ Á : á æ á Á ~ • c {
 [] ǫ } • Á á Á ~ á Á : Á [c @ Á & @ á ~ ^ • È

ÄÜ@ , Á @ [{ æ * : æ •

ÄÜ@ , Á @ æ á : Á á Á [c : Á } Á & ç :

ÄÜ@ & ` á^ Á ^ ^ æ á Á ~ } Á [* •

ÄÜ@ & ` á^ Á : á } • æ & ǫ } Á [* •

GY'WYX'G][bUhi fY'Cdh]cbg

Üææ • K Ó Ò Ò Á Á [ǫ [& ^ á

ÄÜ^ [: ǫ * Á á á & Á Á [, ^ á Á @ Á Ò Ò

7 i ghca Yf'5 ddfcj U

Pæ ^K

Väi^K

Öæ^K

Ùä }æ`!^K

Pæ ^K

Väi^K

Öæ^K

Ùä }æ`!^K

Pæ ^K

Väi^K

Öæ^K

Ùä }æ`!^K

Pæ ^K

Väi^K

Öæ^K

Ùä }æ`!^K

